Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

756
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
756
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
Pericarditis IV: Nursing Management01:25

Pericarditis IV: Nursing Management

2
Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
2
Increased pulse rate01:17

Increased pulse rate

646
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
646
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

2
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
2

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Taking Bold Steps for Meaningful Changes in Transplant Cardiology Fellowship Training.

Clinical transplantation·2026
Same author

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026
Same author

Clinical Characteristics and Outcomes of Older Patients Admitted to the Cardiac Intensive Care Unit.

JACC. Advances·2026
Same author

Associations Between Admission C-Reactive Protein and In-Hospital Mortality Amongst Patients with Cardiogenic Shock.

European heart journal. Acute cardiovascular care·2026
Same author

Early Corticosteroid use and Clinical Outcomes in Patients with Mixed and Cardiogenic Shock.

Journal of intensive care medicine·2026
Same author

Impact of "Door-to-Lactate Clearance" on Clinical Outcomes in Cardiogenic Shock.

JACC. Heart failure·2026

Related Experiment Video

Updated: Jun 8, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K

Tailored Therapy in Cardiogenic Shock: Case-Based Management Choices.

S Shiva Patlolla1, Amit H Alam2, Jason N Katz2

  • 1Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, Texas.

The American Journal of Cardiology
|November 3, 2024
PubMed
Summary

A tailored approach to cardiogenic shock (CS) improves patient outcomes. Recognizing distinct CS phenotypes and their unique hemodynamic profiles guides diagnosis and treatment, moving beyond a one-size-fits-all strategy.

Keywords:
cardiogenic shockhemodynamicsmechanical supportphenotypes

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.5K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

21.0K

Related Experiment Videos

Last Updated: Jun 8, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.5K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

21.0K

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Hemodynamics

Background:

  • Cardiogenic shock (CS) is a life-threatening condition characterized by cardiac dysfunction and hypoperfusion.
  • Current CS management often uses a generalized approach, overlooking significant patient heterogeneity.
  • This lack of phenotype-specific understanding challenges clinical trials and patient care.

Purpose of the Study:

  • To highlight the importance of phenotype-specific management in cardiogenic shock.
  • To demonstrate how understanding unique hemodynamic profiles can guide targeted therapies.
  • To advocate for a tailored approach over a generalized strategy for CS treatment.

Main Methods:

  • Review of representative cases of cardiogenic shock phenotypes: acute myocardial infarction, acute-on-chronic heart failure, fulminant myocarditis, and right ventricular failure.
  • Analysis of specific hemodynamic parameters relevant to each phenotype.
  • Discussion of the underlying pathophysiology and its implications for treatment.

Main Results:

  • Distinct CS phenotypes exhibit unique hemodynamic profiles.
  • Specific hemodynamic parameters aid in diagnosing and guiding therapy for each phenotype.
  • Pathophysiology informs predictions for treatment response and need for mechanical support.

Conclusions:

  • A phenotype-tailored approach to cardiogenic shock, considering unique hemodynamic profiles, is superior to a one-size-fits-all strategy.
  • This personalized approach can improve diagnostic accuracy and therapeutic targeting.
  • Implementing phenotype-specific management may lead to better patient outcomes in cardiogenic shock.